- Home
- WHWK vs STRO Comparison
WHWK vs STRO Comparison
Compare WHWK & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | STRO |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | 128 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 181.4M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WHWK | STRO |
|---|---|---|
| Price | $3.20 | $11.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $7.71 | ★ $47.23 |
| AVG Volume (30 Days) | ★ 284.5K | 260.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,145,000.00 | ★ $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $0.72 |
| 52 Week High | $5.50 | $43.85 |
Technical Indicators
Market Signals| Indicator | WHWK | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 28.47 |
| Support Level | $2.46 | $10.52 |
| Resistance Level | $3.05 | $16.99 |
| Average True Range (ATR) | 0.18 | 1.24 |
| MACD | -0.05 | -0.21 |
| Stochastic Oscillator | 13.64 | 15.95 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.